In this article (9 sections)
Finasteride at the 1 mg dose used for male pattern hair loss has been on the market since 1997, and the 5 mg dose used for benign prostatic hyperplasia (BPH) has been studied for even longer. That gives us a longer post-marketing safety record than almost any other medication in dermatology. This page summarizes what the long-term data actually shows, where the evidence is strong, and where genuine uncertainty remains.
Long-term safety questions are reasonable, and they deserve a careful answer rather than a reassuring one. The decision to start or continue treatment is best made with a clinician who can weigh your individual history against the published evidence.
The shape of the long-term evidence base
Finasteride has been studied in several large, multi-year trials and tracked in registry data for more than two decades. The pivotal phase III trials for hair loss enrolled men aged 18 to 41 and followed cohorts for up to five years, with extension data in smaller groups stretching to ten years. Separately, the 5 mg dose for BPH has been studied in trials enrolling tens of thousands of older men over four-year and seven-year horizons.
Two of the most cited long-term datasets come from prostate-focused research: the Prostate Cancer Prevention Trial (PCPT), which followed roughly 18,000 men on finasteride 5 mg or placebo for seven years, and the REDUCE trial, which followed roughly 8,000 men on dutasteride or placebo for four years (Andriole et al., NEJM, 2010). These were not hair-loss studies, but they generated the cleanest available long-horizon safety signal for 5-alpha reductase inhibition in general.
The 1 mg hair-loss dose produces a smaller pharmacologic effect than the 5 mg BPH dose, so most safety signals seen at 5 mg should, if anything, be milder at 1 mg. Where direct hair-loss data exist, we use those; where they don't, the BPH literature is the closest analogue.
Prostate cancer risk
The relationship between finasteride and prostate cancer is the long-term safety topic that has generated the most confusion, and it has evolved over time.
In the PCPT, men on finasteride 5 mg had a lower overall rate of prostate cancer compared to placebo (roughly 18 percent vs 24 percent over seven years), but among the cancers that did occur, a slightly higher proportion were classified as high-grade. This led to an FDA label revision in 2011 noting a possible increased risk of high-grade disease.
Subsequent re-analyses of the same data, accounting for the fact that finasteride shrinks the prostate (making sampling more efficient and high-grade cancers easier to detect), found that the apparent increase in high-grade tumors was largely a detection artifact rather than a true biological effect. An 18-year follow-up of PCPT participants published in 2019 found no increase in prostate-cancer-specific mortality or all-cause mortality in the finasteride group compared to placebo.
The current consensus, reflected in updated guidance from the American Urological Association and the Endocrine Society, is that 5-alpha reductase inhibitors do not increase overall prostate cancer mortality. The 1 mg dose used for hair loss has not been associated with any prostate cancer signal in its own trials.
Cardiovascular safety
There is no consistent signal that finasteride at either dose increases cardiovascular events. The PCPT did not show a difference in cardiovascular mortality between finasteride and placebo over its seven-year horizon, and the long-term extension data agree. Some smaller observational studies have looked at lipid profiles and found no clinically meaningful change.
Patients sometimes ask whether finasteride affects blood pressure or heart rate. It does not have a recognized direct cardiovascular pharmacology, and the trial record does not show meaningful changes in these parameters.
Hepatic and renal safety
Finasteride is metabolized primarily in the liver. Routine liver function testing is not recommended for healthy patients on the 1 mg dose, because clinically significant hepatic effects have not been seen in the long-term trial data. Rare case reports of elevated liver enzymes exist, almost always reversing on discontinuation. The medication is not nephrotoxic, and renal function is not a typical monitoring concern.
Patients with pre-existing liver disease should discuss the medication with their physician, because clearance can be altered.
Persistent sexual and neuropsychiatric symptoms
This is the area where the evidence is most contested and where it matters most to be candid about what we do and don't know.
A subset of patients have reported sexual side effects (decreased libido, erectile dysfunction, reduced ejaculate volume) that did not resolve after stopping the medication, sometimes accompanied by mood changes, cognitive complaints, or anhedonia. This constellation has been described in the literature as post-finasteride syndrome (PFS). Patient registries and case series document the phenomenon; randomized trials were not designed to detect it and have not consistently reproduced it as a defined syndrome.
The current evidence does not allow a clean estimate of how often persistent symptoms occur, which patients are at higher risk, or what the underlying mechanism is. Proposed mechanisms include altered neurosteroid metabolism and androgen receptor changes, but none have been definitively established. Regulatory agencies in Europe and the US have updated finasteride labeling to acknowledge reports of persistent sexual side effects and, in some jurisdictions, depression and suicidal ideation.
What's reasonable to take from this:
- The vast majority of patients who experience side effects on finasteride see them resolve when they stop the medication or even while continuing it.
- A smaller subset report persistent symptoms, and these reports deserve to be taken seriously rather than dismissed.
- Patients with a history of depression, anxiety, or pre-existing sexual dysfunction may want to have a more cautious conversation with their physician about whether the risk-benefit balance fits them.
- If new sexual, mood, or cognitive symptoms develop on the medication, the appropriate response is to talk to a prescriber promptly rather than push through.
The companion guide is finasteride safe long term and the dedicated discussions in finasteride side effects and sexual side effects of finasteride go into more depth on this topic, as does does finasteride cause permanent side effects.
All-cause mortality
The cleanest summary of long-term safety is whether people on the medication live as long as people not on it. In the available follow-up data, including the 18-year follow-up of PCPT, there is no increase in all-cause mortality associated with finasteride use. That is a reassuring signal at the population level. It does not, on its own, answer questions about quality-of-life outcomes for individuals who develop persistent symptoms.
Practical considerations for long-term use
Most men who start finasteride for androgenetic alopecia continue indefinitely if the medication is working and tolerated, because stopping reverses the benefit over roughly 6 to 12 months. The decision to commit to long-term use is therefore really a decision about whether the side-effect profile fits your risk tolerance and life situation.
Some patients on long-term therapy choose:
- An annual check-in with a prescribing clinician to discuss tolerability and any new symptoms.
- A baseline conversation about topical finasteride as a lower-systemic-exposure alternative, if systemic effects are a concern.
- Combining with minoxidil to maintain results on a lower finasteride dose, where appropriate.
PSA testing is sometimes mentioned in long-term safety discussions. The 1 mg dose lowers PSA values modestly (in the range of 40 to 50 percent reduction over time at the 5 mg dose, less at 1 mg). Anyone over 40 who does prostate cancer screening should make sure their physician knows they are on finasteride so PSA values can be interpreted correctly.
Considering long-term treatment with medical support
Long-term safety questions are exactly the kind of question that benefits from a conversation with a clinician rather than a self-assessment. The published evidence supports the medication as broadly safe at the population level over decades of follow-up, but individual risk factors, current symptoms, and personal tolerance for uncertainty all matter.
If you want to understand whether oral finasteride fits your situation, you can start an assessment and connect with a licensed clinician who can review your history and answer your specific questions. The how it works page explains the process.
